Eli Lilly has announced positive results from the Phase 3 EVOLVE-1 and EVOLVE-2 trials looking into Emgality (galcanezumab-gnlm) for the treatment of episodic migraine.
The drug was found to reduce the number of migraine headache days patients experienced each month, in comparison to placebo.
Patients – who were categorised as either low-frequency (four to seven migraine days a month) or high-frequency (eight to 14 monthly migraine days a month) – were given either 120mg or 240mg doses of Lilly’s Emgality.
